Impact of Matrix Metalloproteinase 9 on COPD Development in Polish Patients: Genetic Polymorphism, Protein Level, and Their Relationship with Lung Function

Table 1

Characteristics of the analyzed groups.

Groups (N)	Age	Sex	FEV1	FEV1/FVC	Smokers
	(years)	(women/men)	(% predicted)	(% predicted)	(%)
COPD (335)	67.9 ± 9.2	248/87	55.5 ± 18.5	52.2 ± 16.0	100
CTR (309)	68.0 ± 6.6	80/229	91.7 ± 22.8	89.2 ± 25.8	35.5
CTR smokers (110)	68.4 ± 5.2	73/37	93.3 ± 22.0	91.1 ± 19.5	100
CTR non-smokers (199)	65.8 ± 9.6	157/42	91.0 ± 23.6	88.1 ± 28.7	0
COPD (60)	70.4 ± 9.0	13/47	46.6 ± 18.5	58.1 ± 16.4	100
CTR (61)	67.8 ± 6.7	46/15	90.4 ± 22.5	92.6 ± 23.2	37.7
CTR smokers (23)	67.7 ± 5.6	15/8	93.2 ± 21.9	88.2 ± 16.4	100
CTR non-smokers (38)	67.9 ± 7.6	31/7	90.6 ± 22.0	90.7 ± 18.0	0

N, numbers of individuals; COPD, chronic obstructive pulmonary disease groups; CTR, control group; , groups for CNV and protein levels analyses; FEV₁, forced expiratory volume in 1 second; FEV₁/FVC, Tiffeneau-Pinelli index; ratio of forced expiratory volume in 1 second and forced vital capacity; , difference to the control group statistically significant at the level of p<0.00001.